Fig 2: OBFC2A is an independent prognostic factor for patients with breast cancer. (A–C) OBEC2A mRNA expression is higher in high-grade samples and TNBC subtype. (D) OBFC2A was negatively associated with OS of breast cancer (P < 0.05). (E, F) OBFC2A mRNA expression was negative associated with OS of all grade breast cancer(P < 0.05). (G, H) Univariate Cox and Multivariate Cox regression analyses were performed in CPTAC. (I, J) ROC curves of OBFC2A expression to predict OS of three year (0.790) and five year (0.959) in CPTAC and TNBC subtype (0.815) in METABRIC.

Fig 3: OBFC2A plays a role in promoting the development of breast cancer. (A, C) OBFC2A protein expression is also higher in TNBC subtype and cell lines of TNBC (MDA-MB-231, BT549, YCCB1). (B, D) Western blot analysis confirmed the silencing efficacy; (E, F) Colony formation assay with cells transfected with NC or OBFC2AshRNA (12-well plate); (G, H) OBFC2A-silenced MDA-MB-231 cell exhibited significantly decreased cell motility. Flow cytometry was used to analyze the effects of silencing OBFC2A on cell cycle (I, J) and apoptosis (K, L). Data are presented as mean ± SD, n=3, *p < 0.05, **P < 0.01, ***p < 0.001.